Vera Therapeutics Inc
VERAHealthcare|Biotechnology|USA
$42.00
-0.45 (-1.06%)
Tangible Book
$6.97
Earnings Power
$7.21
Clinical Trials (24)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06958588 Pulsed Electromagnetic Field Therapy or Pneumatic Compression VTE Prophylaxis | Venous Thromboembolism (VTE), Intensive Care Medicine | P4 | Recruiting | 50 | Single-blind | — |
| NCT04716231 Atacicept in Subjects With IgA Nephropathy | IgA Nephropathy, Berger Disease | P3 | Active | 376 | RCT, Double-blind | Atacicept |
| NCT06983028 Atacicept in Multiple Glomerular Diseases | pMN, IgAN | P2 | Recruiting | 250 | Open-label | Atacicept |
| NCT07020923 Monthly Dosing of Atacicept in IgAN | IgA Nephropathy (IgAN), Berger Disease | P2 | Active | 90 | RCT, Open-label | Atacicept |
| NCT07270445 Effect of Virtual Reality Use on Preoperative Anxiety | Anxiety | N/A | Recruiting | 172 | RCT, Open-label | — |
| NCT01761786 Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics) | Myocardial Infarction, STEMI | P4 | Completed | 2,700 | RCT, Single-blind | — |
| NCT05609812 Atacicept in Subjects With Active Lupus Nephritis (COMPASS) | Lupus Nephritis (LN) | P3 | Withdrawn | — | RCT, Double-blind | Atacicept, Placebo |
| NCT03166527 Panzyga in CIDP Administered at Different Infusion Rates | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | P3 | Unknown | 30 | Open-label | Immune Globulin 10% Intravenous Solution |
| NCT04294472 A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients | BK Virus Infection | P2 | Completed | 30 | RCT, Double-blind | MAU868 |
| NCT06674577 A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept | IgA Nephropathy (IgAN), Renal and Urinary Disorders | P2 | By Invite | 750 | Open-label | Atacicept 150 mg |
| NCT02101385 Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer | Malignant Neoplasm of Breast, Breast Cancer | P2 | Completed | 193 | RCT, Open-label | Genomically Directed Monotherapy |
| NCT04315987 NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia | COVID-19 Pneumonia | P2 | Completed | 90 | RCT, Double-blind | NestaCell®, Placebo |
| NCT04536363 Cri Analog PG1 Effectiveness and Safety in Covid-19 | Covid19 | P2 | Withdrawn | — | RCT, Open-label | Analogs, Prostaglandin E1, Standard therapeutic protocol |
| NCT04849364 Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer | Breast Cancer, Triple Negative Breast Cancer | P2 | Terminated | 52 | Open-label | Capecitabine, Talazoparib, Pembrolizumab, Inavolisib |
| NCT07251777 Prone vs Supine Position in Potential Organ Donors: Multicenter Clinical Trial | Prone Position, Donors | N/A | Completed | 254 | RCT, Open-label | — |
| NCT02427945 Leveraging an Existing Large-scale Safe Water Program to Deliver Nutrition Messages at a Low Marginal Cost | Child Malnutrition | N/A | Completed | 1,671 | RCT, Single-blind | — |
| NCT03660228 Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS | Myelodysplastic Syndromes | N/A | Completed | 62 | Open-label | — |
| NCT04348409 Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19 | COVID-19 | N/A | Completed | 50 | RCT, Double-blind | Nitazoxanide Tablets, Placebo |
| NCT05451225 Survey of Correction Officers Before and After a Targeted Education Campaign | Work-Related Condition | N/A | Completed | 451 | Open-label | — |
| NCT07291466 Assessment of Preoperative Anxiety and Evaluation of Calming Interventions: Anonymous Patient Survey | Anxiety | Completed | 750 | — | — | |
| NCT03962348 Clinical Interviews With Detainees With Early Psychosis | First-Episode Psychosis | N/A | Completed | 8 | Open-label | — |
| NCT03450304 Lung Perfusion Measured With Dual-Energy CT in Patients With Chronic Thromboembolic Pulmonary Hypertension: Comparative Study With Right Heart Catheterization and V/Q | Multidetector Computed Tomography, Pulmonary Embolism and Thrombosis | Unknown | 30 | — | — | |
| NCT03060018 Transcutaneous Partial Oxygen and Carbon Dioxide Pressures Compared With Blood Gas Values | Critical Illness | N/A | Completed | 113 | Open-label | — |
| NCT03525990 Study Evaluating the Impact of Electronic Surveys on Patient-physician Communication and Quality of Life in Breast Cancer Patients | Breast Neoplasm Malignant Female | N/A | Completed | 62 | RCT, Open-label | — |